Genprex’s Reqorsa combo secures Canadian patent for lung cancer

Genprex has received a Notice of Allowance from the CIPO for a patent related to the use of its Reqorsa gene therapy in combination with either PD-1 or PD-L1 antibodies to treat NSCLC and SCLC.